Monarsen    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
11Myasthenia1

11. Myasthenia    [ 226 clinical trials,   172 drugs,   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways]
Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 226 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002740-26-GB
(EUCTR)
21/02/200601/12/2005A Phase II Double Blind, Cross-Over Study to Compare the Safety and Efficacy of 10, 20 and 40 mg Monarsen (EN101) administered to Patients with Myasthenia GravisA Phase II Double Blind, Cross-Over Study to Compare the Safety and Efficacy of 10, 20 and 40 mg Monarsen (EN101) administered to Patients with Myasthenia Gravis Myasthenia Gravis
MedDRA version: 8.1;Level: LLT;Classification code 10028417;Term: Myasthenia gravis
Ester Neuroscience LtdNULLNot Recruiting Female: yes
Male: yes
30Phase 2United Kingdom